Inotersen vs Vutrisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Transthyretin Amyloidosis with Polyneuropathy
Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline
Inotersen · Tegsedi
Rights held by Ionis Pharmaceuticals and partners
NCT01737398 · Phase 2/3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 172 patients. Both co-primary endpoints, a validated neuropathy impairment score and a quality-of-life questionnaire, showed statistically significant benefit with inotersen versus placebo at week 66.
No aligned efficacy figure on record for this race.
Vutrisiran · AMVUTTRA
Marketed by Alnylam Pharmaceuticals
NCT03759379 · Phase 3 · completed
This was a randomized but open-label study, and its primary comparison used 122 vutrisiran-treated participants versus 77 participants from an external APOLLO placebo group rather than a concurrent blinded placebo arm. The clinical primary endpoint, change in mNIS+7 at Month 9, favored vutrisiran and was statistically significant, but the lack of blinding and use of an external comparator limit the strength of the evidence.
Reported efficacy
Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) (met)
Result source: NCT03759379
Results for Transthyretin Amyloidosis with Polyneuropathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Inotersen: registry results are on file for Transthyretin Amyloidosis with Polyneuropathy, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inotersen's landscape · Vutrisiran's landscape